Published in J Biol Chem on January 28, 2003
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res (2008) 1.54
HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat Struct Mol Biol (2012) 1.52
Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol (2010) 1.50
Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem (2009) 1.45
Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem (2008) 1.42
The kinetic and chemical mechanism of high-fidelity DNA polymerases. Biochim Biophys Acta (2010) 1.38
Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem (2009) 1.37
Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Viruses (2010) 1.24
Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J Biol Chem (2009) 1.17
HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors. Viruses (2010) 1.06
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother (2004) 1.06
Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2007) 1.03
Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. Antimicrob Agents Chemother (2012) 1.01
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir. Antimicrob Agents Chemother (2007) 0.99
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology (2013) 0.90
Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage. Nucleic Acids Res (2014) 0.88
Structural requirements for RNA degradation by HIV-1 reverse transcriptase. Nat Struct Mol Biol (2013) 0.87
4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem (2014) 0.87
FASTDXL: a generalized screen to trap disulfide-stabilized complexes for use in structural studies. Structure (2007) 0.87
NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A (2013) 0.86
Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors. Viruses (2014) 0.85
Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet. ACS Chem Biol (2016) 0.85
Rate-limiting Pyrophosphate Release by HIV Reverse Transcriptase Improves Fidelity. J Biol Chem (2016) 0.84
Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant. Cell Mol Biol (Noisy-le-grand) (2012) 0.84
HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate. Viruses (2010) 0.82
Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer. J Biol Chem (2013) 0.81
Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase. J Biol Chem (2014) 0.79
Purification, crystallization and preliminary X-ray diffraction of a disulfide cross-linked complex between bovine poly(A) polymerase and a chemically modified 15-mer oligo(A) RNA. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.78
Structures of reverse transcriptase pre- and post-excision complexes shed new light on HIV-1 AZT resistance. Viruses (2011) 0.76
Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA). Proc Natl Acad Sci U S A (2016) 0.75
Kinetic pathway of pyrophosphorolysis by a retrotransposon reverse transcriptase. PLoS One (2008) 0.75
Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem (2004) 6.55
Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe (2010) 3.08
Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol (2008) 2.88
Inhibition of bacterial RNA polymerase by streptolydigin: stabilization of a straight-bridge-helix active-center conformation. Cell (2005) 2.88
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A (2008) 2.82
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J (2002) 2.41
Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol (2010) 2.31
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem (2005) 2.31
Structural basis of transcription initiation. Science (2012) 2.23
Structural basis for suppression of a host antiviral response by influenza A virus. Proc Natl Acad Sci U S A (2008) 2.02
H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell (2013) 2.00
The RNA polymerase "switch region" is a target for inhibitors. Cell (2008) 1.96
Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol (2005) 1.93
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc Natl Acad Sci U S A (2002) 1.85
HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol (2006) 1.83
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol (2003) 1.80
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol (2004) 1.78
A conserved structural module regulates transcriptional responses to diverse stress signals in bacteria. Mol Cell (2007) 1.76
Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol (2007) 1.69
Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc Natl Acad Sci U S A (2010) 1.68
Crystal structure of a benzo[a]pyrene diol epoxide adduct in a ternary complex with a DNA polymerase. Proc Natl Acad Sci U S A (2004) 1.66
Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol (2010) 1.65
Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochemistry (2002) 1.64
Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (2007) 1.61
Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem (2006) 1.55
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res (2008) 1.54
The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol (2002) 1.53
PCR amplification of DNA containing non-standard base pairs by variants of reverse transcriptase from Human Immunodeficiency Virus-1. Nucleic Acids Res (2004) 1.52
HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat Struct Mol Biol (2012) 1.52
Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol (2010) 1.50
Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure (2009) 1.50
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J Med Chem (2005) 1.48
Crystal structure of LeuA from Mycobacterium tuberculosis, a key enzyme in leucine biosynthesis. Proc Natl Acad Sci U S A (2004) 1.44
Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol (2004) 1.44
r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene in human urine: a potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiol Biomarkers Prev (2003) 1.41
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum (2009) 1.38
Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem (2009) 1.37
Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol (2002) 1.36
2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol (2008) 1.36
Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol (2012) 1.35
A structural gap in Dpo4 supports mutagenic bypass of a major benzo[a]pyrene dG adduct in DNA through template misalignment. Proc Natl Acad Sci U S A (2007) 1.33
Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J Mol Biol (2006) 1.31